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Abstract
Background: Tpr is a large coiled-coil protein located in the nuclear basket of the nuclear pore complex for which many
different functions were proposed from yeast to human.
Methodology/Principal Findings: Here we show that depletion of Tpr by RNA interference triggers G0–G1 arrest and
ultimately induces a senescent-like phenotype dependent on the presence of p53. We also found that Tpr depletion impairs
the NES [nuclear export sequence]-dependent nuclear export of proteins and causes partial co-depletion of Nup153. In
addition Tpr depletion impacts on level and function of the SUMO-protease SENP2 thus affecting SUMOylation regulation at
the nuclear pore and overall SUMOylation in the cell.
Conclusions: Our data for the first time provide evidence that a nuclear pore component plays a role in controlling cellular
senescence. Our findings also point to new roles for Tpr in the regulation of SUMO-1 conjugation at the nuclear pore and
directly confirm Tpr involvement in the nuclear export of NES-proteins.
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Introduction
Nuclear pore complexes (NPCs) mediate all selective bidirection-
al transportbetween thenucleusand thecytoplasm. Evidence isalso
emerging pointing to additional roles for NPCs, their constituent
proteins (nucleoporins) and associated transport proteins, some of
which are independent of classical transport [1,2]. It may therefore
reasonably hypothesized that NPCs are key in pathological cell
conditions where abnormal cell growth is a central feature.
The protein Tpr (for translocated promoter region) and its
homologues are a conserved component at the nuclear side of NPC.
In mammals Tpr is a 267-kDa structural protein with a long N-
terminal domain that associates in a dimer to form a parallel, two-
stranded coiled-coil. The C-terminal domain is highly acidic and is
predicted to be unstructured [3]. In mammalian cells Tpr is
restricted to the nucleoplasmic fibrils of the NPC and it has been
suggested that it acts as the main architectural element of the
nuclear basket [4,5]. Mammalian Tpr is tethered to NPC through
interactions with Nup153 [5,6,7,8]. Many functions have been
attributed to Tpr and its homologues in different species in addition
to a role in NPC architecture. These include mRNA export control
[9,10], nuclear protein export [4,11], silent telomeric chromatin
organization and telomere length control [12,13,14]. In addition,
Drosophila and human Tpr have been shown to be involved in
spindle checkpoint control [15,16,17] and human Tpr in the
control of Erk2 nucleo-cytoplasmic translocation [18].
Tpr homologues in yeast, Mlp1p-Mlp2p, are involved in
attaching SUMO-protease Ulp1p to NPC [19,20]. This
functional interaction seems to be conserved in Arabidopsis
thaliana between ESD4 and NUA, which are homologues of
Ulp1p and Tpr, respectively [21]. SUMOylation corresponds to
the post-translational conjugation of SUMO (small ubiquitin-
related modifier protein) to a specific lysine residue in a target
protein. SUMOylation is mediated by an enzymatic cascade
reaction involving successively a SUMO-activating enzyme or
E1 and a unique E2 SUMO-conjugating enzyme, Ubc9. SUMO
modification is reversible since SUMO-specific proteases can
deconjugate the SUMO moiety from the modified proteins
suggesting that protein SUMOylation is dynamically regulated
in cells [22,23]. Among the Ulp1p-related SUMO-proteases
that have been characterized in mammals, SENP1 and SENP2
show the greatest similarity with yeast Ulp1 and are also
associated with the nuclear envelope. Ulp1p and SENP2 share
the property of being targeted at NPC by their non-catalytic N-
terminal domains [24]. However, in vertebrates, the N-terminal
N P C - t a r g e t i n gd o m a i ni nS E N P 2interacts with the C-terminal
domain in Nup153, but not with Tpr [25,26].
Cellular senescence was first described as ‘‘replicative senescence’’
b e c a u s eo ft h el i m i t e dl i f es p a no fh uman diploid fibroblasts in vitro
[27]. Studies in cancer cells have shown that, despite the fact that they
are able to divide indefinitely, a state closely resembling replicative
senescence can be acutely induced by various stimuli such as
chemotherapeutic agents and radiation. This therefore represents
another cell program, besides apoptosis, that can limit cell proliferation
[28,29]. Senescent cells are characterized by enlarged cell size,
flattened morphology, inability to synthesize DNA, and expression
of senescence-associated (SA)-b-galactosidase, the biomarker of
senescence [30].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22423We report here that Tpr is critical for cell proliferation and that
Tpr depletion leads to a senescence-like phenotype that is
dependent on p53. Also, Tpr down-regulation impacts on the
nuclear export of proteins with a Crm1-dependent nuclear export
sequence (NES). Levels of Nup153 and SENP2 function at the
nuclear pore are also affected. As a consequence substantial
changes were observed in the pattern of SUMO-1 conjugation at
NPC and within the cell.
Results
Tpr knockdown induces G0–G1 arrest and a senescent
phenotype in HeLa cells
Tpr has recently been described to have several different
functions but its role in cell cycle, cell fate and proliferation has
never been fully assessed. We thus investigated the effect of Tpr
depletion on the cell cycle using siRNAs targeting Tpr in HeLa
cells. We found that the level of Tpr protein was specifically
reduced after 48 hours of treatment with either of the two
synthetic siRNAs used, as shown by western blot analysis of total
cell extracts of treated HeLa cells (Fig. 1A and S1A).
We then determined the location in HeLa cells by confocal
microscopy (Fig. 1B). Optical sections through the center of the
nucleus showed the punctuate pattern characteristic of nucleopor-
ins at the NE. Exposure to siRNAs directed against Tpr
dramatically reduced the punctuate Tpr pattern at the NE
(Fig. 1B). Since Tpr was efficiently down regulated under these
conditions, we were able to analyze its role in cell growth and
viability. We found that treatment with Tpr siRNAs impaired cell
proliferation as compared to mock siRNA-treated cells (Fig. 1C).
To investigate whether this was due to halted cell proliferation or
cell death, cells were treated with Annexin-V and propidium
Figure 1. Cell cycle effects of Tpr depletion in HeLa cells. HeLa cells seeded in 24-well plates at 5 10
24 cells per well were treated with Tpr or
mock siRNAs. 1A. 48 hours after siRNA treatment as indicated on top of the figure, a cell extract was prepared and analyzed by western blotting using
anti-Tpr Mab 203-37; tubulin was used as loading control. 1B. Bright field image (right panel) and confocal image (left panel) of HeLa cells labeled
with an anti-Tpr monoclonal antibody after 2 days of transfection with Tpr or mock siRNA. Scale bar: 5 mm. 1C. Growth curve of HeLa cells transfected
with Tpr, mock siRNA or not transfected: control (Ctrl). 1D. Representative FACS profiles of mock siRNA treated (left panel), Tpr siRNAs treated cells
(center) and non-transfected cells or control (right). Ethanol-fixed cells were incubated with PI and analyzed by FACS for ploidy. Cell number is
represented on the vertical axis and DNA content on the horizontal axis. G0–G1 and G2-M phases are represented as first and second peaks starting
from the vertical axis, respectively. The intermediate striped domain corresponds to the S phase. 1E. Induction of senescence: cells were plated at low
density and treated with Tpr or mock siRNAs. After 6 days, cells were fixed and stained for SA-b-gal activity at pH 6.0. Scale bar: 20 mm. 1F.
Quantification of SA-b-gal positive cells in cultures depleted of Tpr and stained for SA-b-gal activity at pH 6.0. 1G–1H. U2OS cells were transfected
with Tpr or mock siRNAs. 1G: After 6 days the cells were fixed and stained for BrdU incorporation and SA-b-gal activity at pH 6.0. Scale bar: 15 mm. 1H:
After 6 days, the cells were labeled with anti-HP1c and anti-MacroH2A antibodies and DAPI. Scale bar: 5 mm. 1I: A375 cells were transfected with Tpr
or mock siRNAs. After 6 days the cells were fixed and stained for SA-b-gal activity at pH 6.0. Scale bar: 15 mm.
doi:10.1371/journal.pone.0022423.g001
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by fluorescence-activated cell sorting (FACS). No gross difference
between the Tpr siRNA-treated cells and the controls was
observed, indicating that the growth defect was not due to
apoptosis (data not shown).
To further characterize the effect of Tpr knockdown on cell
proliferation, we analyzed cell cycle distribution of Tpr siRNA-
treated cells and controls by measuring their DNA content by
FACS. We noted that mock siRNA transfection did not affect the
cell cycle of HeLa cells as compared to untreated cells. By contrast,
the cell cycle was arrested at the G0–G1 phase in Tpr knockdown
cells as shown in Fig. 1D. Approximately 46% of the control
transfected and untransfected cells (2 days post-transfection) were
in the G0–G1 phase of the cell cycle, whereas 69% of the Tpr
knockdown cells were in G0–G1. At the same time, approximately
37–38% of control cells progressed to the S phase compared with
only 16% of the Tpr knockdown cells (Fig. 1D). The same
proportion of cells were seen in the G2-M phase under all three
conditions. Similar results were obtained with the two Tpr siRNA
sequences (Fig. S1B).
We then performed a colony-forming assay as an independent
measurement of the proliferation defect triggered by Tpr
depletion. A substantial decrease (36%) in the number of colonies
was apparent when cells were transfected with Tpr siRNAs
compared to mock-transfected cells (Fig. S1C). These results
suggest that transfecting HeLa cells with Tpr siRNAs dramatically
slowed tumor cells proliferation.
A more careful examination of the Tpr siRNA-treated cells
showed that a fraction of these had a rather ‘‘severe’’ phenotype in
that they had the appearance of senescence with a grossly
expanded cytoplasm. This led us to conduct further investigations
focused on this particular response. In transient RNAi assays, the
time course for effective depletion of the target protein is not more
than four days while Tpr knockdown cells were arrested in G0–
G1. Meanwhile non-transfected cells continue to divide and
rapidly overtake non-dividing cells. We therefore established
conditions under which cells were plated at low density (5.10
4 to
10
5 per well in a 6 well-plate) to minimize the effect of
overgrowing non-transfected cells.
Experiments under these conditions showed that a large fraction
of the population started to change morphology 3–4 days after
transfection: cells were enlarged and flattened (Fig. 1E). A major
test for senescence is SA-b-galactosidase activity measured at
acidic pH [30] and 6 days post-transfection, most of the enlarged
and flattened cells were b-gal positive and colored blue (about
40%) in Tpr knockdown wells, whereas senescent-like blue cells
were rare (around 10%) in the mock treated cell (Fig. 1F).
Tpr siRNA knockdown also induced senescence in two other
tumor cell lines, U2OS, a human osteosarcoma cell line, and A375
human melanoma cells (Fig. 1G–1I). BrdU staining showed that
SA-b-galactosidase positive cells were BrdU negative (Fig. 1G). In
addition, Tpr siRNAs-treated U2OS cells and controls were
labeled with antibodies specific for histone variant macro-H2A
and HP1c, two markers of heterochromatin constitutive of the
SAHF (senescence associated heterochromatin foci) that were first
identified in senescent human fibroblasts [31,32]. Many macro-
H2A and HP1c positive and colocalizing foci were observed in
U2OS senescent cells nuclei, whereas they were absent in control
nuclei. Brighter DAPI dots indicating heterochromatin colocalized
with macro-H2A and HP1c labeling can be seen in Fig. 1H.
Tpr depletion induces nuclear accumulation of p53
As the p53 pathway is often involved in blocking tumor
development by triggering cellular senescence or apoptosis in
response to stress it was important to evaluate cell p53 status when
Tpr is depleted.
We first used immunocytochemistry to analyze the distribution
of p53 and at the same time studied the effect of Nup153 depletion
as this has been shown to delocalize Tpr from the nuclear pore to
the nuclear interior. As shown in Fig. 2A, the p53 signal appeared
as intense punctuate labeling in the nuclei of Tpr- and Nup153-
depleted cells. No signal was observed in control cells. By
comparison, whereas depletion of Nup133, a scaffold nucleoporin
that plays an important role in nuclear pore structure and
function, does not induce any nuclear accumulation of p53 [33],
such accumulation was seen in Tpr-depleted U2OS cells (data not
shown). These results show that Tpr depletion or mislocalization
lead to nuclear accumulation of p53.
The cyclin-dependent kinase inhibitor (CDK) p21 is elevated in
many stressful conditions and is transcriptionally regulated by p53.
We therefore investigated the consequences of Tpr depletion on
levels of p53 and p21. Levels of p53 and p21 were both up-
regulated in Tpr-depleted Hela cells (Fig. 2B) and U2OS cells
(Fig. 2C). In addition, when evaluated in cell extracts where both
Tpr and p53 were depleted, p21 accumulation was seen to be
lower than with Tpr siRNAs alone (Fig. 2C). This observation
indicates that part of the p21 accumulation noted is due to
activation of p53. Levels of the CDK inhibitors p16
INKA (Fig. 2B)
and cyclinD1 were also increased in Tpr-depleted HeLa cells (data
not shown).
Finally, in order to demonstrate formally the role played by p53
in mediating the induction of senescence in Tpr-depleted cells, we
co-depleted both Tpr and p53. Knocking down both Tpr and p53
resulted in a substantial reversion of the senescence phenotype as
assessed by the percentage of SA-b-galactosidase-positive cells
(Fig. 2D).
Tpr depletion interferes with NES-dependent nuclear
export
It has been suggested that the low steady-state levels of p53 in
normal cells, i.e. in the absence of cellular stress, result from
continuous Crm1-dependent nuclear export [34] and subsequent
cytosolic degradation of p53. Also, Tpr was recently found to
interact with Crm1 in an trimeric export complex [11]. We may
therefore hypothesize that Tpr leads to p53 nuclear accumulation
and stabilization by blocking its nuclear export.
To test this hypothesis we first used the construct pSTAT1-
NES-GFP, which encodes residues 367–427 of human STAT1
that confers NES activity [35], to prevent additional regulatory
events interfering with the inhibition of Crm1-dependent nuclear
export. This construct was co-transfected with Tpr, Crm1 and
control siRNAs to probe for NES-dependent export. As shown in
Fig. 3A, the distribution of the GFP signal in live cells 48 hours
after transfection showed that Crm1- and Tpr-depletion led to
substantial nuclear retention of the NES-GFP construct whereas
GFP remained mainly cytosolic in mock-treated cells. The cells
were then permeabilized and labeled with Crm1 and Tpr
antibodies to check depletion efficiency (Fig. 3B).
A functional Crm1-dependent NES is also required for
IkappaBepsilon-mediated nuclear export that controls the nu-
cleo-cytoplasmic distribution and post-induction nuclear clearance
of NFkB/Rel proteins [36]. To better assess the effect of Tpr
depletion on the NES-nuclear export of an endogeneous protein,
HeLa cells were first transfected with Tpr or mock siRNAs two
days prior to NFkB induction by TNF. As shown in Fig. 3C–3D,
Tpr depletion delayed the clearance of NFkB from the nucleus as
compared to mock treated cells. It is worth noting that NFkB
Tpr Knockdown Induces Senescence
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22423Figure 2. p53 is stabilized and accumulates in the nuclei of Tpr-depleted cells. 2A. Analysis of p53 distribution in HeLa cells by
immunofluorescence. Upper panel: HeLa cells were transfected with Tpr, Nup153 and mock siRNAs as indicated on the left; lower panel: HeLa cells
were transfected with Nup133 and mock siRNAs. The cells were fixed at day 2 post -transfection and labeled with an anti-Tpr antibody (top left
panels) or anti-Nup133 (bottom left panel) and an anti-p53 (right top and bottom panels). 2B. Hela cell whole cell protein lysates were separated by
SDS-PAGE and immunoblotted with antibodies specific for Tpr, p53, p21, p16 and tubulin as indicated in the figure. 2C. Whole cell protein lysates of
U2OS cells treated with Tpr, Tpr+p53 or control (mock) siRNAs were separated by SDS-PAGE and immunoblotted with antibodies specific for Tpr, p53,
p21 and tubulin as indicated in the figure. 2D. Co-depletion of p53 and Tpr reversed senescence induction. Cells were transfected with mock, Tpr, p53
or Tpr and p53 in combinations as indicated. The final siRNA concentration was 100 nM in each case and compensation was made with mock siRNAs.
Cells were labeled for SA-b-galactosidase at 6 days post-transfection and the result is given as the percentage of SA-b-galactosidase positive cells in
each of the three independent experiments.
doi:10.1371/journal.pone.0022423.g002
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different in mock- and Tpr-siRNAS treated cells (Fig. 3C).
We then sought to determine whether Tpr depletion affects
Crm1 levels and distribution, or vice-versa. To do this we
transfected HeLa cells with siRNAs directed against Tpr and,
Crm1, or mock transfected HeLa cells, and 48 hours later we
treated the cells with Tpr- and Crm1-specific antibodies.
Immunofluorescent analysis for Crm1 expression in control and
Crm1 knock-down cells showed reduced levels in the nucleoplasm
and nuclear envelope of the Crm1 siRNA-transfected cells. Also
Tpr expression was substantially reduced in Tpr siRNAs-treated
cells. By contrast, Crm1 expression did not appear to be affected
by Tpr depletion and Tpr was not affected in Crm1 knock-down
cells (Fig. S2A–B).
Tpr depletion impacts on the expression and distribution
of Nup153 and SENP2 in the nuclear basket
To better assess the role of Tpr in nuclear pore organization and
function, we examined more carefully the relationship between
Tpr and Nup153 by measuring their levels in total extracts of cells
transfected with Tpr or Nup153 siRNAs. As shown by western
blot analysis of total cell extracts (Fig. 4A), cell treatment with
Nup153 siRNAs led to almost complete disappearance of Nup153
and a marked decrease in Tpr. This decrease in Tpr levels was
consistent with previous studies showing that Tpr is mislocalized to
the nuclear interior in Nup153 knockdown cells [8]. Likewise,
treatment with Tpr siRNAs led to a marked decrease in Tpr and a
greatly reduced Nup153 signal (Fig. 4A). We next confirmed this
observation by immunofluorescence analysis in HeLa cells treated
with Tpr siRNAs and labeled with antibodies directed against
different components of the nuclear envelope. Labeling with an
anti-emerin antibody and the Mab414 antibody that recognizes all
FG-repeat-containing nucleoporins including Nup153 was not
grossly modified (Fig. 4B–4C). By contrast, we found that labeling
with a specific anti-Nup153 antibody was reduced (Fig. 4B–4C).
We concluded from these observations that Tpr depletion
specifically affects level of Nup153 protein at the NE.
Given that Tpr depletion altered Nup153 distribution at the
nuclear pore and that Nup153 tethers SENP2 to the NPC, we
hypothesized that Tpr may impact on SENP2 protein levels and
function. To test this hypothesis, we evaluated the effect of Tpr
depletion on SENP2. Firstly, given that no antibody is available to
observe endogenous SENP2 in fixed cells, we analyzed SENP2
levels in nuclear extracts of cells depleted in Tpr, Nup153 or
SENP2 and in mock depleted cells. Tpr depletion in HeLa and
293 cells was accompanied by a reduction in SENP2 to levels very
similar to those observed in SENP2-depleted extracts. Then to
compare the different protein levels, we monitored Nup133 and
TRF2 as a loading control for nuclear extracts (Fig. 4D and S3A).
Depletion of Nup153 similarly induced a reduction in SENP2
(data not shown).
Tpr depletion affects SUMOylation
The finding that Tpr depletion affects SENP2 prompted us to
address the question of whether Tpr depletion might interfere with
the SUMOylation of other proteins. In order to investigate
changes in the overall SUMOylation of proteins, HeLa cells were
treated with Tpr, SENP2 and control siRNAs and nuclear and
cytoplasmic extracts were analyzed and compared by western
blotting using an anti-SUMO-1 antibody. Blots of nuclear extracts
showed that SENP2 repression caused an accumulation of high
molecular weight SUMO-1 as was expected for a decrease in
SUMO-protease activity. No such accumulation was seen in
mock-transfected cells. By contrast, Tpr-depleted cells showed
lower overall SUMOylation than compared siRNAs transfected
cells (Fig. 5A). Similar results were obtained in U2OS and 293 cells
(Fig. S3B and data not shown). Consequently, free SUMO-1 was
seen to accumulate in Tpr-depleted cells (Fig. S3C).
RanGAP1 (Ran-GTPase activating enzyme 1) is an abundantly
SUMOylated protein and most anti-RanGAP1 antibodies detect
the SUMO-1-modified form and the SUMO-free RanGAP1,
migrating around 80 kDa and 70 kDa, respectively. We thus
examined the effect of Tpr depletion on the distribution and the
level of expression and SUMOylation of RanGAP1. The fraction
of SUMO-free RanGAP1 detected by this antibody was increased
in cytosolic extracts of Tpr- and SENP2-siRNAs treated compared
to mock treated HeLa cells (Fig. 5B) and in U2OS whole cell
extracts (Fig. S3B). In the nuclear extract fraction, only SUMO-1-
RanGAP1 was detected and found to be increased in Tpr- and
SENP2-siRNAs treated cells compared to mock treated cells when
detected with anti-SUMO-1 and anti-RanGAP1 antibodies, with
the increase being more pronounced in Tpr-treated cells than in
SENP2-treated cells (Fig. 5A).
So far, the role of protein SUMOylation in senescence
induction has only been studied in normal fibroblasts. We have
verified that depletion of SENP2 could induce senescence in
U2OS cells in our experimental setting (Fig. S3D). To better assess
the contribution of the SUMO-1 modification pathway to the
Tpr-induced senescence phenotype in cancer cells, we performed
in parallel RNAi knockdown of Tpr, SUMO-1 and combined
SUMO-1 and Tpr. After 6 days, cells were fixed and analyzed for
SA-b-galactosidase staining. The total cell number was dramat-
ically different between the Tpr alone condition and the two other
conditions. Forty or 50 fields were counted for each condition: the
number of fields containing blue cells and the percentage of space
occupied by enlarged blue cells were evaluated (Table 1). In fact,
for SUMO-1 depleted cells, most fields were filled with cells at
saturation density meaning that the cell proliferation was not
stopped. Very few blue cells were observed: 3 (in one field) to
about 20 blue cells or so could be enumerated in 7 fields only, the
rest being negative. In the end, the results were so different that it
was impossible to include them in Table 1. As a matter of fact
there were less SA-b-galactosidase positive cells in the SUMO-1
Figure 3. Analysis of Crm1 dependent NES-proteins nuclear export in Tpr depleted cells. 3A–3B. Distribution of GFP in cells co-
transfected with STAT1-NES-GFP and Tpr, Crm1 or control (mock) siRNAs. 3A: GFP distribution was analyzed in live cells. Nuclei were labeled with
Hoechst 33342. Scale bar: 10 mm. 3B: Cells were then permeabilized and labeled with antibodies specific for Tpr and Crm1 and DAPI for the DNA. Top
panel: Tpr depletion and control; lower panel: Crm1 depletion and control. Scale bar: 10 mm. 3C–3D: Tpr depletion delays nuclear export of NFkB.
HeLa cells were transfected with Tpr or mock siRNAs 2 days prior to NFkB induction. Transfected and control cells were then incubated with TNF
100 IU/mL for 40 min. TNF was then removed from the medium and the cells were either fixed or kept for another 1h30 in fresh medium before
fixation. 3C: Quantification of the NFkB signal: All images were acquired at the same magnification and exposure and the NFkB signal was quantified
using the same surface area in the nuclei and cytoplasm of cells under the different experimental conditions using OpenLab3.1.2. The cytosolic signal
was plotted against the nuclear signal and standard deviation was calculated using Microsoft Excel. Error bars represent the standard deviation. Note
that the cytosolic to nuclear signal ratio is very similar in control cells before TNF treatment and 1h30 after TNF removal. This was as expected and is
due to NFkB fully returning to the cytoplasm at this time. 1h30 after TNF removal the cytosolic to nuclear signal ratio was about 25% lower in the Tpr-
depleted cells than in the control cells. 3D: Immunofluorescent labeling of NFkB and Tpr 1h30 after TNF removal in Tpr-depleted and control cells.
Fixed cells were labeled with a rabbit anti-NFkB antibody and anti-Tpr mAb 203-37.
doi:10.1371/journal.pone.0022423.g003
Tpr Knockdown Induces Senescence
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22423depleted cells than in the mock control. The results described in
Table 1 show that the population as a whole was affected by Tpr
depletion whereas cells with a senescent-like phenotype were far
more dispersed in the Tpr plus SUMO-1 condition. In addition,
with few exceptions, most blue cells did not exhibit a full senescent
phenotype as they were not flattened and the SA-b-galactosidase
staining was faint (Fig. 5C).
Discussion
We have demonstrated in this study that depleting Tpr is
sufficient to induce a senescent-like phenotype in tumor cell lines.
The senescence phenotype can be explained by the accumulation
of several growth-suppressive proteins acting on mitogenic signal
transduction and cell cycle regulation. Two main signaling
pathways, p16INK4a–pRb and p14ARF–p53, are responsible
for the execution of proliferative arrest that characterizes
senescence [37,38]. The Rb-p16 pathway is defective in both
HeLa and U2OS cell lines but p53 in U2OS and HeLa cells and
p16 in HeLa cells are increased after Tpr knockdown. P53
accumulates in the nucleus and so does p21/CIP1, a downstream
effector that is involved in several forms of G1 checkpoint control.
Furthermore, part of the p21/Cip1protein up-regulation is
dependent on the presence of p53.
In normal cells, p53 is a target of the ubiquitin-proteasome
pathway: the low levels of p53 result from continuous Mdm2-
mediated nuclear export of p53 for cytosolic degradation. In HeLa
cells, nuclear export is also necessary for degradation of p53
mediated by the human papilloma virus (HPV) 18 E6 protein [39].
We show here that Tpr depletion leads to nuclear retention of a
GFP reporter harboring the NES sequence of STAT1 and delays
the post-induction nuclear clearance of NFkB after TNF removal
in HeLa cells [36], two events dependent upon the Crm1 export
factor. Tpr was recently found to interact with Crm1 in the
presence of an NES peptide or an NES peptide plus RanGTP like
in a trimeric export complex [11]. Although the molecular details
of this interaction have not been further characterized, the absence
of Tpr is likely to impair the function of Crm1 in nuclear export.
We found that Tpr knock-down weakly affects Crm1 levels in
western blot experiments but does not obviously impact on Crm1
levels as measured using specific antibodies on fixed cells.
However, it has previously been reported that even slight
downregulation of Crm1 results in prominent defects in nuclear
export [40]. Crm1 inhibition also reduced cell proliferation and
Figure 4. Analysis of Nup153 and SENP2 proteins in Tpr-depleted cells. 4A. HeLa cells were transfected with mock, Tpr or Nup153 siRNAs as
indicated on the top. Whole cell lysates were analyzed 2 days post-transfection by immunoblotting using antibodies directed against Tpr, the anti-FG
repeat nucleoporin Mab414 to label Nup153 and Nup62 and anti-tubulin as loading control. 4B–4C. Nup153 expression is specifically lowered in Tpr-
depleted cells. HeLa cells were treated with Tpr2 or mock siRNAs for 2 days. 4C. Cells were fixed and labeled with an anti-Tpr antibody and anti-
emerin, anti-Mab414 or anti-Nup153 antibodies. Scale bar: 15 mm. 4D. Details from Mab414 and Nup153 labeling. Scale bar: 5 mm. 4D. Analysis of
SENP2 expression in nuclear extracts of 293 cells treated with Tpr, SENP2 and mock siRNAs by western blot analysis. TRFII is used as a loading control.
doi:10.1371/journal.pone.0022423.g004
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as previously reported [41]. We thus favor the hypothesis that a
main consequence of Tpr depletion is the nuclear accumulation
and activation of p53 by inhibition of its nuclear export.
In support of this, leptomycin B (LMB), a Crm1 inhibitor, has
been shown to reduce E6’s ability to degrade p53 in cervical
carcinoma cells [39,42] and cause: (i) retention of STAT1-NES
construct in the nucleus [34,35], (ii) nuclear accumulation and
activation of p53, (iii) induction of specific downstream target
genes of p53 [42–45] and (iv) growth arrest and a senescent-like
phenotype primary prostate epithelial cells and fibroblasts.
Consistently with this, we show here that nuclear accumulation
of p53 is accompanied by growth arrest and senescence in HeLa,
U2OS and A375 cells, as characterized by enlarged and flattened
SA-b-galactosidase-positive and BrdU-negative cells. Chromatin
foci were labeled with HP1c and macro-H2A antibodies, two
markers of SAHF, in the nuclei of senescent U2OS cells [31,32].
Finally, the induction of senescence is substantially alleviated when
p53 is co-depleted with Tpr.
We also reported that Tpr depletion induces a marked decrease
in Nup153 total cell content and at the NPC. In addition to
causing a nuclear redistribution of Tpr [8], Nup153 knockdown is
accompanied by a decrease in total cell Tpr content (this paper).
Fluorescence recovery after photo bleaching measurements of the
association of Nup153 with NPCs showed that Nup153 exists as a
fast and a slower exchanging pool [46] and it has been suggested
that the slower fraction may anchor Tpr at the nuclear basket [47].
Indeed, the effect of Tpr depletion on Nup153 is partial, which
may explain why the observation in fixed cells required substantial
Tpr depletion. Only a fraction of the Nup153 was affected by this
Tpr depletion whereas Nup153 depletion has more profound
effects on Tpr. The mechanism by which the depletion of one
protein leads to at least partial degradation of the other partner
has not yet been analyzed.
Tpr depletion was expected to impinge on SENP2 as this
interacts directly with Nup153 in human cells [25,26]. We
observed that SENP2 levels decreased in Tpr-siRNAs treated
cells in the same range as in SENP2-siRNAs treated cells.
However, whereas siRNA-mediated depletion of SENP2 led to an
accumulation of high-molecular-mass SUMO-1-modified species,
consistent with decreased SUMO-protease activity, Tpr depletion
had the opposite effect with decreased levels of high-molecular-
mass SUMO-1-modified species. SUMOylation is a highly
dynamic post-translational modification, and loss of SUMOylation
may result either from decreased SUMO conjugating activity or
increased SUMO protease activity.
SENP2 is a shuttling, predominantly nuclear, protein and
depends on Crm1 for its nuclear export [48]. The importance of
NPC localization for the correct regulation of SENP2 activity has
already been emphasized as mutants of the NLS region - the
interaction region with Nup153- are unable to locate at the
nuclear pore and they show enhanced SUMO-protease activity
[25]. Therefore the changes in SUMOylation may be attributed to
altered SENP2 localization and regulation in the absence of Tpr,
presumably with SENP2 being retained in the nucleus as a Crm1-
export dependent protein. Altered SENP2 regulation may have
several consequences. Firstly, selective modifications of proteins by
either SUMO-1 or SUMO-2/3 [49,50] affect their sub-cellular
distribution and function [49,50]. Notably, SUMO-1 is distributed
only to NPCs [51] and to the mitotic spindle during mitosis [52],
and altered localization and function of different checkpoint
proteins was described during mitosis in Tpr-depleted cells
[15,16,17]. Secondly, it was recently proposed that selective
modification of RanGAP1 and probably other targets by SUMO-
1 or SUMO-2/3 is determined at the deconjugation level by
Figure 5. Tpr regulates SUMOylation. 5A–5B. Analysis of the
overall level of SUMOylation in cells transfected with Tpr, Nup153,
SENP2 and mock siRNAs. 5A. Nuclear extracts of siRNAs treated cells
were prepared and analyzed by western blotting using the antibodies
as described on the left of the figure. RPB1 was used as loading control.
5B. Analysis of RanGAP1 SUMOylation. Cytoplasmic extracts of Tpr,
Nup153, SENP2 and mock siRNAs-treated cells were prepared and
analyzed by western blotting using an anti-RanGAP1 antibody
recognizing both SUMOylated and non-SUMOylated forms of RanGAP1
and with tubulin as loading control. 5C: SUMO-1 siRNA treatment
overrides Tpr depletion-induced senescence in HeLa cells. HeLa cells
were transfected with Tpr, SUMO-1, Tpr and SUMO-1 and mock siRNAs.
After 6days, the cells were fixed and stained for SA-b-gal activity at
pH 6.0. A representative picture of each condition is presented. Scale
bar: 15 mm.
doi:10.1371/journal.pone.0022423.g005
Table 1. Effects of SUMO-1 depletion on Tpr-induced
senescence.
SABS (%) 0 5–10 25–40 .40
Tpr a 19 (4) 45 (13) 34 (16)
Tpr+SUMO-1 59 (6) 37 (6) a 0
After 6 days cells transfected with Tpr or Tpr and SUMO-1, as described in
Fig. 5C, were analyzed for SA-b-galactosidase staining. Forty to fifty fields were
counted for each condition: the number of fields containing blue cells and the
percentage of space occupied in each field by enlarged blue cells were
evaluated. SABS: percentage of space occupied by blue cells in a field. Results
are given as percentages of fields in the four categories for Tpr or Tpr+SUMO-1
experiments. Numbers between round brackets correspond to standard
deviation. (a): only one field with blue cells was observed.
doi:10.1371/journal.pone.0022423.t001
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activity could induce a shift in the spectrum of SUMO conjugation
from SUMO-1 to SUMO 2/3 in Tpr-depleted cells. Interestingly,
it has been reported that the stable overexpression of SUMO 2/3
induces a senescent phenotype in 293 cells, probably by mimicking
the stress-induced elevation of SUMO 2/3 [54].
Surprisingly, Tpr depletion and SENP2 have similar effects on
RanGAP1, with increased amounts of SUMO-free RanGAP1 in the
cytoplasm and SUMO-1-RanGAP1 at the nuclear envelope. An
increase in total RanGAP1 has previously been reported in conditions
of cellular stress [55,56]. In SENP2 depleted cells, higher levels of
SUMO-1 conjugation may render free SUMO-1 less available for
conjugation in the vicinity of the nucleus, thus affecting the
SUMOylation of cytosolic RanGAP1, as previously observed [57].
Tpr depletion has a direct impact on the nuclear export of
proteins [4,11] (this paper). Therefore, Tpr may play a
complementary role in protein retention in the nucleus, acting in
concert with SENP2, the impairment of which may result in
altered function and sub cellular localization of particular targets,
notably transport factors, nucleoporins and transcription factors.
In addition, it is conceivable that Tpr, Nup153 and SENP2, given
their interdependency, are organized into a complex whose
function is modified when any of its constituents are depleted.
Altogether, our data underline the evolutionary conservation of
the role of Tpr, in association with Nup153, in docking a SUMO
protease and regulating SUMO conjugation at the NPC
[19,20,24]. Initially, the association of E3 ligases and isopeptidases
with NPCs suggested that import and export were coupled with
modification and de-modification, respectively [58]. SUMOyla-
tion processes are now known to be associated with other roles for
NPCs including cell division, DNA repair, DNA replication and
mRNA quality control. More recently, a systematic genomics
approach aimed at evaluating the relationship between the
SUMO pathway and functionally associated proteins in yeast,
identified many components of the NPC and associated factors,
notably Mlp1p and Mlp2p, as SUMO conjugates, and Crm1p as a
SUMO direct and indirect interactor [59].
Finally, we observed that co-depletion of SUMO-1 with Tpr
nearly abrogated the senescence induced by Tpr depletion. It may
therefore be hypothesized that SUMO-1 depletion corrects the
accumulation of free SUMO-1 in Tpr-depleted cells. In support of
this, under normal conditions SUMO-1 appears to be mainly
conjugated to target proteins, while unconjugated pools of SUMO
2/3 species are abundant and available. However, in contrast with
SUMO 2/3 [54], SUMO-1 overexpression does not seem to have
a direct effect on the process of cellular senescence [60].
Therefore, the exact contribution made by decreased SUMO-1
conjugation and an enlarged pool of free SUMO-1 to Tpr-induced
senescence is not clearly understood at present, whether in
conjunction with p53 or not. Up until now it was agreed that
disruptions in the SUMO pathway that result in increased levels of
SUMOylated proteins would trigger senescence [61,62]. Our
observations do not exclude the possibility that increased SUMO
modifications contribute to the execution of the senescence
program and that its knockdown precludes completion of this
program. Further experiments will be necessary to clarify these
issues along with the molecular mechanisms involved.
Materials and Methods
Cell lines and culture conditions
HeLa cells, A375, 293 and U2OS cells were obtained from
ATCC. All cells were cultured in DMEM Glutamax (invitrogen),
10% fetal calf serum and 5% CO2.
RNA interference and DNA constructs
Two siRNA Tpr sequences were designed corresponding to 141–
159 nt (dsTpr2) and 1381–1399 nt (dsTpr1) of the Tpr human coding
sequence (GenbankNM_003292; V. Cordes,personal communication
and reference [63],respectively).DsTpr2 was used inmost experiments
as Tpr siRNA. Another sequence, Tpr iv [64], was tested in senescence
induction (Fig. S2). Other siRNAs corresponded to Nup133 (a gift from
V. Doye), Nup153 (Qiagen) and a non-targeting siRNA (Dharmacon,
Eurogentec). Other siRNAs were synthesized at Dharmacon and
Eurogentec. SENP2 siRNAs corresponded to sense GGUAACUU-
CUGCUUGUAAU?d(TT) [65] and sense GAUCAGAGUGACA-
GUUACC?d(TT) [66], SUMO-1 siRNA: sense CUGGGA AUG-
GAGGAAGAAG?d(TT) [67], p53 siRNA: sense CAGUCU ACC-
UCCCGCCAUA.d(TT) [68], Crm1 siRNA sense UGUGGUGAA-
UUGCUUAUAC?d(TT) [69].
HeLa cells were seeded in 24-well dishes at a concentration of 5
10
4. 6 hours later, the cells were transfected with 3 ml Oligofecta-
mine or with 1 ml Lipofectamine RNAiMax and 3 ml siRNAs
(20 mM). Forty-eight hours after transfection, protein levels were
analyzed by Western blot analysis or cells were fixed for
immunofluorescence studies.
Growth curves, cell cycle and apoptosis analysis
HeLa cells were seeded as described in triplicate and transfected
with Tpr siRNAs, mock siRNAs or not transfected. The cells were
trypsinized and counted every day after transfection.
Apoptotic cell death was determined by measuring surface
exposure of phosphatidylserine. Double staining for Annexin-V-
Fluorescein and propidium iodide (PI) was performed using the
Annexin-V-FLUOS staining kit (Roche). Cells that stained positive
for PI (dead cells) were excluded from the analysis. Data were
a c q u i r e do naF A C S C A L I B U Rc y t o m e t e ra n da n a l y z e du s i n g
CellQuest software (both Becton–Dickinson, Pont de Claix, France).
In the cell cycle distribution analysis, cells were harvested every
day, fixed overnight in 70% ethanol, washed and incubated with
100 mg/mL RNAseA and 10 mg/mL propidium iodide in PBS for
1/2 hour at RT. Samples were analyzed for DNA content and cell
size on a FACSCALIBUR cytometer using standard methods.
30 000 gated events were counted for each sample. The histogram
data were curve fitted and percentage cells in each phase of the cell
cycle were estimated using Modfit software.
Clonogenic cell survival assay
HeLa cells were transfected with Tpr-specific siRNAs and mock
controls in duplicate. 48 hours after transfection, cells were
counted and seeded in triplicate 100 mm dishes as 100 cells per
dish. The cells were then left to grow for 15 days. Colonies were
stained with 0.5% crystal violet solution in 25% ethanol and
counted.
BrdU incorporation
For BrdU incorporation, cells were pulsed with 10 mmol/L
BrdUrd for 14 h at 37uC. Cells were fixed in 3,2% PFA. DNA was
denatured by acid treatment (2 M HCl) and BrdU was labeled
with a mouse anti-BrdU-FITC antibody (BD Pharmingen
TM).
Assay of the senescence-associated b-galactosidase
Cells were fixed in 2% formaldehyde/0.2% glutaraldehyde at
room temperature for 5 min, and incubated at 37uC with a fresh
staining solution (1 mg/ml of 5-bromo-4- chloro-3-indolyl b-D-
galactoside, 40 mM citric acid-sodium phosphate (pH 6.0), 5 mM
potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM
NaCl, and 2 mM MgCl2) [30].
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HeLa cells were transfected with Tpr or mock siRNAs 2 days
prior to NFkB induction. Transfected and control cells were then
incubated with TNF 100 IU/mL (Pharmingen) for 40 min. TNF
was then removed from the medium and the cells were either fixed
or kept for another 1h30 in fresh medium before fixation.
Antibodies
The following antibodies were used: mouse 203-37 (Oncogene
research) and 3B9 (Santa Cruz) and rabbit (a gift from L. Gerace)
anti-Tpr, mouse (DO1) and rabbit anti-p53, goat anti-Nup133,
mouse anti-p16, goat anti-Crm1, rabbit anti-NFkB (Santa Cruz),
mouse anti-Nup153 (Progen and SA-1, a gift from B. Burke),
mouse anti-emerin (Novacastra), mouse anti-FG nucleoporins
Mab414 (Eurogentec and Covance), goat anti-RanGap1 anti-
body (a gift from F. Melchior), mouse anti-p21 (Calbiochem),
rabbit anti-SENP2 (Abgent and Calbiochem), mouse anti-GMP-1
(anti-SUMO-1, Invitrogen), mouse anti-Rb (BD Pharmingen),
rabbit anti-TRF2 (Novus biologicals), rabbit anti-histone
macroH2A1 (Active Motif), mouse anti-HP1c and mouse anti-
RPB1(Euromedex), mouse anti-actin AC-40 and anti-a tubulin
DM1A (SIGMA).
We were also provided with anti-Tpr rabbit polyclonal
antibodies prepared by Covalab (Lyon, France) against a
combination of peptides corresponding to aa 2049–2070 and aa
2324–2349 of the human Tpr coding sequence coupled to KLH.
Immuno-fluorescence microscopy
Cells were fixed in 3,2% paraformaldehyde, permeabilized in
Triton X-100 (0.4% in phosphate-buffered saline, PBS) and
stained subsequently with specific antibodies at the appropriate
dilution in PBST 5% milk. DAPI (SIGMA) was used to visualize
the nuclear compartment. Immunofluorescence analysis was
performed using a DMRX4 fluorescence microscope and images
were taken with a Hamamatsu ORCAII-ER cooled CCD-camera
and processed with OpenlabH software (Improvision). Some
images were acquired on a Zeiss Axiophot fluorescence micro-
scope fitted with an Olympus DP71 camera running Olympus
Cell‘A software for image acquisition.
The pSTAT1-NES-GFP construct encodes residues 367–427 of
human STAT1, which confers NES activity [35]. HeLa cells were
co-transfected with this construct and Tpr, Crm1 and control
siRNAS with JetPrimeTM following the manufacturer’s instruc-
tions. 48 hours later, live cells were labeled with Hoechst 33342
and directly analyzed for GFP distribution by fluorescence
microscopy. The cells then were fixed with 3,2% PFA,
permeabilized and then labeled with anti-Crm1 and Tpr
antibodies and Alexa fluor 546-anti-goat and Alexa fluor 488-
anti-mouse secondary antibodies. Nuclei were labeled with DAPI.
Western blot analysis
Whole cell extracts were prepared in RIPA buffer (50 mM Tris,
pH 8.1/150 mM NaCl/0.2% SDS/1% sodium deoxycholate/1%
Nonidet P-40/5 mM EDTA) or ProteoJET
TM Mammalian cell
lysis reagent (Fermentas) containing proteases inhibitors (Roche)
and 1 mM PMSF. Nuclear and cytoplasmic extracts were
prepared using the ProteoJET
TM cytoplasmic and nuclear protein
extraction kit (Fermentas). In the SUMOylation analysis, 10 mM
iodoacetamide were added to all buffers.
Supporting Information
Figure S1 Comparison of Tpr1 and Tpr2 siRNA deple-
tion efficiency. S1A: HeLa cells seeded as 5 10
24 cells per well
in 24-well plates were treated with Tpr1, Tpr2 or mock siRNAs.
At 24 hours (d1), 48 hours (d2) or 72 hours (d3) after treatment
with the siRNAs as indicated at top of the figure, a cell extract was
analyzed by western blotting using anti-Tpr Mab 203-37. Nup62
revealed by the Mab414 antibody was used as a loading control.
S1B: Cell-cycle distribution in Tpr1, Tpr2 and mock siRNAs-
treated HeLa cells. Cell cycle distribution in Tpr1, Tpr2 and mock
siRNA-treated cells 3 and 4 days after transfection analyzed by
FACS and represented as percentage of the population. S1C.
Colony forming ability after Tpr depletion in HeLa cells: HeLa
cells transfected with Tpr were collected on day 3 of depletion,
counted and plated at different dilutions. Light gray column: mock
siRNA-treated cells; dark grey column: Tpr siRNA.
(TIF)
Figure S2 Analysis of Crm1 expression and distribution
in HeLa cells by immunofluorescence. S2A–S2B. HeLa
cells were transfected with Tpr, Crm1 and mock siRNAs as
indicated on the left. The cells were fixed on day 2 post-
transfection and labeled with an anti-Crm1 antibody and DAPI
(S2A), anti-Tpr antibody and DAPI (S2B, top panel), anti-Crm1
and DAPI (S2B, lower panel). Scale bar: 10 mm.
(TIF)
Figure S3 Tpr depletion induces senescence in U2OS
cells. S3A. Analysis of the expression of SENP2 in nuclear
extracts of 293 cells treated with Tpr, SENP2 and mock siRNAs
by western blotting analysis. Nup133 is used as a loading control.
S3B. U2OS cells were transfected with mock or Tpr siRNAs. Two
days post-transfection, whole cell lysates were analyzed by
immunoblotting using antibodies directed against SUMO-1,
RanGAP1, p53, p21 as indicated on the right. Tubulin was used
as loading control. S3C. Western blot analysis of whole cell protein
extracts of cells treated with Tpr siRNA or mock siRNA-treated
cells. Whole cell extracts were examined for Tpr, SUMO-1
conjugates and free SUMO-1 expression. Tubulin was used as
loading control. S3D. Quantification of SA-b-gal-positive U2OS
cells in cultures depleted of SENP2, Tpr iv and mock depleted.
(TIF)
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